Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy 23andMe (ME) shares

Learn how to easily invest in 23andMe shares.

23Andme Holding Co (ME) is a leading diagnostics & research business based in the US. It opened the day at USD$2.23 after a previous close of USD$2.23. During the day the price has varied from a low of USD$2.22 to a high of USD$2.275. The latest price was USD$2.25 (25 minute delay). 23andMe is listed on the NASDAQ and employs 0 staff. All prices are listed in US Dollars.

How to buy shares in 23andMe

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table. To buy shares in a US-listed company from New Zealand, you'll need to find a trading platform that allows access to US markets.
  2. Open and fund your share trading account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for 23Andme Holding Co. Find the stock by name or ticker symbol – ME – and research it before deciding if it's a good investment for you.
  4. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of ME, depending on your share trading account.
  5. Purchase now or later. Buy your desired number of shares today with a market order or use a limit order to delay your purchase until ME reaches a desired price.
  6. Check in on your investment. Congratulations, you own a part of 23Andme Holding Co. Optimise your portfolio by tracking your stock — and even the business — performs with an eye on the long term.

Compare share trading platforms

Name Product Min. Monthly Fee Available Asset Types Available Markets
BlackBull Markets Share Trading
Shares, ETFs
US, NZ, AU, Funds with exposure to multiple markets
Trade 23,000+ shares and access 80+ global markets across the US, New Zealand, Australia and more, plus benefit from extended trading hours, no monthly fees, 24/6 dedicated local support and a mobile trading app available on both Android and iOS.
Shares, ETFs, Managed Funds, Index Funds
US, NZ, AU, Funds with exposure to multiple markets
Trade and invest in more than 8,000 companies, ETFs and managed funds across New Zealand, the US and Australia.
Shares, ETFs
Sign up to Hatch through Finder and get a $20 top-up when you deposit $100 or more.
Invest in more than 4,700 US companies and over 1,200 exchange-traded funds (ETFs) - no minimum investment or monthly fees.
Tiger Brokers
Shares, ETFs, Options
US, AU, Funds with exposure to multiple markets
Exclusive: Sign up to Tiger Brokers and use code FINDERNZ to receive a $10 stock voucher on your first deposit, as well as a $30 stock voucher if you deposit within 3 days of opening your account. T&Cs apply.
Trade shares in more than 7,000 companies across the US, Australia and Asia, as well as ETFs, options, futures, CBBCs and more. No minimum investment or monthly fees apply.
Shares, ETFs
Sign up through Finder and use referral code "FINDERNZ" for a free stock valued up to US$150.
Trade more than 4,500 US-listed stocks and ETFs through Stake with $0 fees on trades.
Zacks Trade
Zacks Trade
Shares, ETFs, Bonds, Options
US, AU, Funds with exposure to multiple markets
Trade and invest in global shares, ETFs, bonds, and options across more than 90 international exchanges with no inactivity and maintenance fees.

23andMe shares at a glance

Information last updated 2023-03-27.
Previous close$2.23
Change $0.02
Change % 0.8969%
Volume 1,027,500
Information last updated 2023-03-27.
52-week range$2.02 - $6.31
50-day moving average $2.47
200-day moving average $2.85
Wall St. target price$5.69
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.73

23andMe stock price (NASDAQ:ME)

Use our graph to track the performance of ME stocks over time.

23andMe price performance over time

Historical closes compared with the close of $2.25 from 2023-03-24

1 week (2023-03-21) -1.32%
1 month (2023-02-28) -10.36%
3 months (2022-12-28) 8.70%
6 months (2022-09-28) -30.12%
1 year (2022-03-28) -40.00%
2 years (2021-03-26) -78.16%
3 years (2020-03-24) N/A
5 years (2018-03-24) N/A
[/expander_content] [/expander]

23andMe financials

Revenue TTM $307.7 million
Gross profit TTM $132.9 million
Return on assets TTM -17.44%
Return on equity TTM -37.04%
Profit margin -103.07%
Book value $1.64
Market capitalisation $1 billion

TTM: trailing 12 months

23andMe share dividends

We're not expecting 23andMe to pay a dividend over the next 12 months.

23andMe share price volatility

Over the last 12 months, 23andMe's shares have ranged in value from as little as $2.02 up to $6.31. A popular way to gauge a stock's volatility is its "beta".

ME.US volatility(beta: 1.42)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 23andMe's is 1.4179. This would suggest that 23andMe's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

23andMe overview

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited to leverage genetic insights to validate, develop, and commercialize drugs.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involve substantial risk of loss and therefore are not appropriate for all investors. Past performance is not an indication of future results. Consider your own circumstances and obtain your own advice before making any trades.

More guides on Finder

Go to site